未分化甲状腺癌中TBC1D12 5'UTR突变高发
研究采用Sanger测序检测28例未分化甲状腺癌(ATC)、14株甲状腺癌细胞系及1株正常甲状腺细胞系的TBC1D12 5'UTR、GPR126内含子6、SDHD和PLEKHS1启动子、TERT启动子及BRAFV600E突变,并分析TCGA甲状腺癌数据集中PTC的TBC1D12 5'UTR突变。结果显示50%(14/28)ATC存在TBC1D12 5'UTR热点突变,且该突变在PTC中与诊断年龄较大、病理T3/T4期及晚期肿瘤分期相关。
要点
- 50%(14/28)的ATC样本检出TBC1D12 5'UTR两个热点突变。
- PTC中TBC1D12 5'UTR突变与诊断年龄较大、病理T3/T4期及晚期肿瘤分期相关。
- 非编码突变(TERT、SDHD、PLEKHS1启动子、TBC1D12 5'UTR、GPR126内含子6)合计见于82.1%(23/28)ATC样本。
核心结论
- 这项初步研究首次显示TBC1D12 5'UTR突变在ATC中高发,并提示TBC1D12突变与PTC侵袭性特征相关,需在大队列研究中确认。
研究设计与样本
- 研究采用Sanger测序检测28例ATC患者(19例女性、9例男性,中位年龄64岁,四分位距55-71岁)、14株甲状腺癌细胞系及1株正常甲状腺细胞系的TBC1D12 5'UTR、GPR126内含子6、SDHD和PLEKHS1启动子、TERT启动子及BRAFV600E突变状态。
- 通过分析癌症基因组图谱(TCGA)甲状腺癌数据集探讨PTC中TBC1D12 5'UTR突变患病率及其与临床病理特征的关系。
主要发现
- TERT、SDHD和PLEKHS1启动子、TBC1D12 5'UTR及GPR126内含子6的非编码突变合计见于82.1%(23/28)ATC样本。
- TERT启动子突变见于22例(78.6%)样本,GPR126内含子突变见于2例(7.1%)样本,SDHD和PLEKHS1启动子突变均见于1例(3.6%)ATC样本。
- TBC1D12 5'UTR两个热点突变见于14/28(50%)ATC、7/492(1.4%)PTC及1株ATC来源细胞系。
- PTC中TBC1D12 5'UTR突变与诊断年龄较大(突变型60岁 vs 野生型46岁,p=0.003)、病理T3/T4期(85.7% vs 37.7%,p=0.010)及晚期肿瘤分期(85.7% vs 32.5%,p=0.006)显著相关。
局限性
- 原文结论指出该研究为初步研究,TBC1D12突变与PTC侵袭性特征的关联需在大队列研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Anaplastic thyroid cancer (ATC) is a rare but one of the most lethal types of human cancer. Although increasing evidence demonstrated that ATC tumors had a high mutation burden, little is known about the aberrancy of the noncoding genome of ATC except the well-investigated telomerase reverse transcriptase (TERT) promoter mutations. Methods: The mutational statuses of TBC1D12 5' untranslated region (5'UTR), GPR126 intron 6, SDHD and PLEKHS1 promoters, as well as the TERT promoter and BRAFV600E mutations were determined using Sanger sequencing in 28 patients with ATC (19 women and 9 men) with a median (interquartile range) age of 64 (55-71) years, 14 thyroid cancer cell lines and a normal thyroid cell line. The prevalence of TBC1D12 5'UTR mutations in papillary thyroid cancer (PTC) and their association with clinicopathologic characteristics were explored by analyzing The Cancer Genome Atlas thyroid cancer dataset. Results: The noncoding mutations in TERT, SDHD and PLEKHS1 promoters, TBC1D12 5'UTR, and GPR126 intron 6 were collectively found in 82.1% (23/28) of ATC samples. Specifically, TERT promoter mutations were detected in 22 (78.6%) samples; GPR126 intron mutations were detected in 2 (7.1%) samples; and both SDHD and PLEKHS1 promoter mutations were detected in 1 (3.6%) ATC sample. Two hotspot mutations in TBC1D12 5'UTR were observed in 14 of 28 (50%) ATCs, 7 of 492 (1.4%) PTCs, and 1 cell line derived from ATC. TBC1D12 5'UTR mutations were significantly associated with older age at diagnosis (60 vs. 46 for wild type, p = 0.003), pathological T3/T4 stage (85.7% vs. 37.7%, p = 0.010), and advanced tumor stages (85.7% vs. 32.5%, p = 0.006) in PTC. Conclusions: This preliminary study for the first time showed a high prevalence of TBC1D12 5'UTR mutations in ATC and indicated an association between TBC1D12 mutation and aggressive characteristics of PTC, which needs to be confirmed in large cohort studies.
引用
- Hu G, Xue J, Yu J, et al. High Prevalence of TBC1D12 5'UTR Mutations in Anaplastic Thyroid Cancer. Thyroid. 2024. PMID: 39682039. doi:10.1089/thy.2024.0345
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。